- Home
- CAPT vs NRXS Comparison
CAPT vs NRXS Comparison
Compare CAPT & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPT
- NRXS
- Stock Information
- Founded
- CAPT 2005
- NRXS 2011
- Country
- CAPT South Korea
- NRXS United States
- Employees
- CAPT N/A
- NRXS N/A
- Industry
- CAPT Blank Checks
- NRXS
- Sector
- CAPT Finance
- NRXS
- Exchange
- CAPT Nasdaq
- NRXS Nasdaq
- Market Cap
- CAPT 16.0M
- NRXS 13.0M
- IPO Year
- CAPT N/A
- NRXS 2023
- Fundamental
- Price
- CAPT $1.23
- NRXS $2.61
- Analyst Decision
- CAPT
- NRXS
- Analyst Count
- CAPT 0
- NRXS 0
- Target Price
- CAPT N/A
- NRXS N/A
- AVG Volume (30 Days)
- CAPT 2.0M
- NRXS 4.9M
- Earning Date
- CAPT 01-01-0001
- NRXS 05-12-2025
- Dividend Yield
- CAPT N/A
- NRXS N/A
- EPS Growth
- CAPT N/A
- NRXS N/A
- EPS
- CAPT N/A
- NRXS N/A
- Revenue
- CAPT $17,389,944.00
- NRXS $2,934,945.00
- Revenue This Year
- CAPT N/A
- NRXS $138,883.78
- Revenue Next Year
- CAPT N/A
- NRXS $118.59
- P/E Ratio
- CAPT N/A
- NRXS N/A
- Revenue Growth
- CAPT 84.70
- NRXS 27.52
- 52 Week Low
- CAPT $0.37
- NRXS $1.33
- 52 Week High
- CAPT $3.57
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- CAPT 64.70
- NRXS 50.48
- Support Level
- CAPT $0.97
- NRXS $2.57
- Resistance Level
- CAPT $1.63
- NRXS $2.82
- Average True Range (ATR)
- CAPT 0.18
- NRXS 0.44
- MACD
- CAPT 0.09
- NRXS -0.05
- Stochastic Oscillator
- CAPT 67.63
- NRXS 10.25
About CAPT Captivision Inc.
Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).